Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Cirmtuzumab
Synonyms
Therapy Description

Cirmtuzumab (UC-961) is a monoclonal antibody that binds to human receptor tyrosine kinase-like orphan receptor 1 (ROR1) and blocks ROR1 signaling, leading to growth inhibition in tumor cells (PMID: 26297272, PMID: 29859176, PMID: 32090643).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cirmtuzumab UC-961 ROR1 Antibody 5 Cirmtuzumab (UC-961) is a monoclonal antibody that binds to human receptor tyrosine kinase-like orphan receptor 1 (ROR1) and blocks ROR1 signaling, leading to growth inhibition in tumor cells (PMID: 26297272, PMID: 29859176, PMID: 32090643).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02860676 Phase I Cirmtuzumab Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 Completed USA 0
NCT02222688 Phase I Cirmtuzumab UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia Completed USA 0
NCT03088878 Phase Ib/II Cirmtuzumab Cirmtuzumab + Ibrutinib Ibrutinib A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Active, not recruiting USA 0


Additional content available in CKB BOOST